KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Total Current Liabilities: 2020-2024

Historic Total Current Liabilities for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Dec 2024 value amounting to $187.5 million.

  • Recursion Pharmaceuticals' Total Current Liabilities rose 42.44% to $155.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $155.1 million, marking a year-over-year increase of 42.44%. This contributed to the annual value of $187.5 million for FY2024, which is 101.21% up from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Total Current Liabilities of $187.5 million as of FY2024, which was up 101.21% from $93.2 million recorded in FY2023.
  • Recursion Pharmaceuticals' Total Current Liabilities' 5-year high stood at $187.5 million during FY2024, with a 5-year trough of $23.1 million in FY2020.
  • For the 3-year period, Recursion Pharmaceuticals' Total Current Liabilities averaged around $127.0 million, with its median value being $100.3 million (2022).
  • Its Total Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 114.89% in 2022, then declined by 7.08% in 2023.
  • Yearly analysis of 5 years shows Recursion Pharmaceuticals' Total Current Liabilities stood at $23.1 million in 2020, then soared by 101.99% to $46.7 million in 2021, then surged by 114.89% to $100.3 million in 2022, then dropped by 7.08% to $93.2 million in 2023, then soared by 101.21% to $187.5 million in 2024.